Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Xencor (XE9) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Xmab412 Monoclonal Bispecific AntibodyNot Applicable - Healthy Adult ParticipantsPhase IRecruitingStudy of XmAb412 in Healthy ParticipantsJul 14, 2026
Xmab541, Xmab808Ovarian CancerPhase IRecruitingPhase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid TumorsMay 11, 2026―
Xmab13676Healthy, Idiopathic Inflammatory MyopathiesPhase IRecruitingA Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune DiseasesDec 03, 2025
PlamotamabRheumatoid ArthritisPhase IRecruitingA Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid ArthritisOct 01, 2025
Xmab942Ulcerative Colitis (Uc)phase1AndPhase2RecruitingStudy of XmAb942 in Healthy Participants and Participants With Ulcerative ColitisSep 20, 2024
Xmab541Ovarian Cancer, Endometrial Cancer, Testicular Germ Cell Tumor, Germ Cell Tumor, Ovarian Germ Cell TumorPhase IRecruitingPhase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsFeb 16, 2024
Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + PemetrexedNonsquamous Non-Small Cell Lung Cancerphase1AndPhase2TerminatedStudy of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLCNov 13, 2023
Xmab808, KeytrudaUrothelial Carcinoma, Colorectal Cancer, Head And Neck Squamous Cell Carcinoma, Castration-Resistant Prostate Cancer, Tnbc - Triple-Negative Breast Cancer, Melanoma Excluding Uveal Melanoma, Non-Small Cell Lung Cancer, Squamous Or Non-Squamous, Renal Cell Carcinoma, Clear Cell, Ovarian Cancer, EpithelialPhase ICompletedPhase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsOct 11, 2022―
Xmab819Clear Cell Renal Cell CarcinomaPhase IRecruitingStudy of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaJun 13, 2022
Vudalimab + Carboplatin + Cabazitaxel, Vudalimab + Olaparib, Vudalimab Monotherapy, Vudalimab + Docetaxel, Vudalimab + Cabazitaxel Or DocetaxelMetastatic Castration-Resistant Prostate CancerPhase IICompletedXmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerAug 05, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Xencor Inc. (CH:XE9) have in its pipeline
Xencor CH:XE9 is currently developing the following drugs: Xmab412 Monoclonal Bispecific Antibody, Xmab541, Xmab808, Xmab13676, Plamotamab, Xmab942, Xmab541, Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed, Xmab808, Keytruda, Xmab819, Vudalimab + Carboplatin + Cabazitaxel, Vudalimab + Olaparib, Vudalimab Monotherapy, Vudalimab + Docetaxel, Vudalimab + Cabazitaxel Or Docetaxel. These drug candidates are in various stages of clinical development as the company works toward FDA approval.